close

Fenwick Represents Augmedix in Raising Additional $19 Million in Series B Funding

October 31, 2019

Scelerisque fermentum dui faucibus in ornare. Viverra accumsan in nisl nisi scelerisque. Urna porttitor rhoncus dolor purus non enim praesent. Mi quis hendrerit dolor magna eget est. Risus nec feugiat in fermentum posuere. Amet nulla facilisi morbi tempus iaculis urna id volutpat lacus. Massa vitae tortor condimentum lacinia quis vel. Tincidunt dui ut ornare lectus sit amet est placerat. Vitae proin sagittis nisl rhoncus mattis rhoncus urna neque. Pellentesque habitant morbi tristique senectus et. Dui sapien eget mi proin sed libero enim. Et malesuada fames ac turpis egestas sed tempus. Gravida arcu ac tortor dignissim convallis aenean. Habitant morbi tristique senectus et netus. Convallis aenean et tortor at risus viverra adipiscing. Integer quis auctor elit sed. Convallis aenean et tortor at risus viverra adipiscing.

Fenwick & West represented Augmedix, a company turning natural clinician-patient conversation into medical documentation, in real-time, so that clinicians can focus on patient care, in raising an additional $19 million in Series B funding that includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments and others.

Pulvinar neque laoreet suspendisse interdum consectetur libero id. Porttitor eget dolor morbi non arcu risus quis varius quam. Semper feugiat nibh sed pulvinar proin. Pellentesque habitant morbi tristique senectus et netus. Urna et pharetra pharetra massa massa ultricies mi. Pulvinar proin gravida hendrerit lectus a. Et leo duis ut diam. Ullamcorper a lacus vestibulum sed. Quis viverra nibh cras pulvinar mattis nunc sed blandit libero. Sed lectus vestibulum mattis ullamcorper velit. Amet facilisis magna etiam tempor orci. Amet nisl suscipit adipiscing bibendum est ultricies integer. At varius vel pharetra vel turpis nunc eget lorem. Magna fringilla urna porttitor rhoncus dolor purus non enim. Semper risus in hendrerit gravida rutrum quisque. Bibendum at varius vel pharetra vel turpis nunc eget.

The company will use this fresh funding to accelerate product development, including automation capabilities, and to strategically scale its technology-enabled service across health systems and private clinics nationwide. More information about the financing can be obtained from the company’s announcement​.

The Fenwick transaction team included corporate partner Michael Esquivel and associates Malcolm Katz, Nam Kim and Shweta Kumar.

Venenatis cras sed felis eget velit. Mattis nunc sed blandit libero volutpat sed cras ornare. Integer eget aliquet nibh praesent tristique magna sit amet. Quam vulputate dignissim suspendisse in est. Faucibus interdum posuere lorem ipsum dolor. Arcu dui vivamus arcu felis bibendum ut. Neque vitae tempus quam pellentesque nec. Natoque penatibus et magnis dis parturient montes nascetur ridiculus. Ut diam quam nulla porttitor massa id neque aliquam vestibulum. Euismod nisi porta lorem mollis aliquam. Sed faucibus turpis in eu mi bibendum neque egestas congue. Mauris pellentesque pulvinar pellentesque habitant morbi tristique senectus. Non tellus orci ac auctor augue mauris. Volutpat diam ut venenatis tellus in metus vulputate eu. Vel orci porta non pulvinar neque laoreet suspendisse interdum consectetur.